Your browser version may not work well with NCBI's Web applications. More information here...
1: Clin Genitourin Cancer. 2008 Sep;6(2):134-7.Click here to read Links

Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Sonpavde G, Hutson TE, Berry WR, Boehm KA, Asmar L.

Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA. guru.sonpavde@usoncology.com

Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was conducted to examine the efficacy and toxicities of sunitinib in metastatic CRPC progressing after 1-2 previous chemotherapy regimens including docetaxel. The primary objective was clinical progression-free survival (PFS) with a 12-week PFS > or = 30% assumed to be of interest. Secondary objectives included prostate-specific antigen (PSA) response, modulation of PSA kinetics, objective response, quality of life, pain, survival, and toxicities. Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity.

PMID: 18824440 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Sunitinib (Sutent® )

    Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that wer...

  • Source: AHFS Consumer Medication Information